摘要
目的观察尿激酶对糖尿病肾脏病(DKD)患者血纤溶酶原激活物抑制物1(PAI-1)的影响及其临床疗效。方法选择在我院住院的DKD患者88例,其中Ⅲ期43例、Ⅳ期45例。将DKDⅢ、Ⅳ期患者分别分为对照组(DKDⅢ-C组、DKDⅣ—C组)和观察组(DKDⅢ-O组、DKDⅣ—O组)。对照组给予常规降糖、保护肾脏及血管紧张素转化酶抑制剂(ACEI)等药物治疗。观察组在常规治疗的基础上给予尿激酶50000U加入100ml生理盐水中静脉滴注,每天1次,共14d。比较各组24h尿白蛋白量、空腹血糖、血肌酐、D-二聚体和血PAI-1水平。结果DKDⅢ—C组和DKDⅣ—C组治疗前、后24h尿白蛋白量、空腹血糖、血肌酐、D-二聚体和血PAI-1均无统计学差异(P〉0.05)。DKDⅢ-O组和DKDⅣ—O组治疗后24h尿白蛋白量和血PAI-1均降低(P〈0.05),而空腹血糖、血肌酐、D二聚体治疗前、后均无统计学差异(P〉0.05)。治疗后,DKDⅢ-O组血PAI-1及24h尿白蛋白下降程度较DKDⅣ—O组明显(P〈0.01)。结论尿激酶可通过降低血PAI-1水平来减少DKD患者尿白蛋白量,对保护肾功能、延缓DKD进展有积极意义,且小剂量应用未增加出血倾向,对DKD是一种安全有效的治疗方法。
Objective To observe the clinical effect of urokinase on plasminogen activator inhib- itor-1 in patients with diabetic kidney disease (DKD). Methods Eighty-eight DKD inpatients in our hospital were chosen, including 43 cases of DKDⅢ, and 45 cases of DKD IV. The patients with DKDⅢ were divided into control group (DKD Ⅲ-C group) and observation group (DKD Ⅲ-O group), and those with DKD Ⅳ were also divided into control group (DKD Ⅳ-C group) and observation group (DKD Ⅳ-O group). The patients in control groups received routine treatments including blood glu- cose-reducing, kidney protection and angiotensin converting enzyme inhibitors (ACEI), and those in observation groups were given 50 000 U urokinase in 100 ml normal saline, once every day, days in addition to the routine treatments. The amount of 24-h urinary albumin, fasting blood glucose, serum creatinine, D-dimer and blood PAI-1 levels were compared. Results Between DKD Ⅲ-C group and DKD Ⅳ-C group before and after treatments, there was no significant difference in the amount of 24- h urinary albumin, fasting blood glucose, serum creatinine, D dimer and blood PAI-1 levels (P〉0. 05). In DKD Ⅲ-O group and the DKD Ⅳ-O group after treatments, the amount of 24-h urinary al- bumin and blood PAI-1 levels were significantly lower than those before treatments (P〈0. 05), but there was no significant difference in fasting blood glucose, serum creatinine and D-dimer before and after treatments (P〉0. 05). After treatment, blood PAI-1 levels and amount of 24-h urinary albumin were reduced more significantly in DKD Ⅲ-O group than in DKD Ⅳ-O group (P〈0. 01). Conclusions Urokinase can decrease the blood PAI-1 levels, resulting the decrease in 24-h urinary albumin in DKD patients,which can protect renal function, and delay progress of DKD. Low doses of urokinasedo not increase the bleeding tendency in DKD.
出处
《临床肾脏病杂志》
2011年第5期207-209,共3页
Journal Of Clinical Nephrology